Publication of PVSRIPO Melanoma Phase 1 Study
in The British Medical Journal
FDA Clearance Obtained
for IND Basket Trial
with PVSRIPO
First Patient Dosed in LUMINOS-102
Revolutionizing cancer care.
PVSRIPO is an investigational intratumoral immunotherapy based on the Sabin type-1 polio vaccine. Learn more about how this novel approach to viral immunotherapy could provide a safer, more effective approach to immune activation against cancer.
Reshaping the Standard of Care for the Treatment of Cancer
Istari Oncology is a clinical-stage biotechnology company focused on developing and commercializing groundbreaking immuno-oncology therapies with the potential to improve the standard of care for a wide range of solid tumors, including glioblastoma and melanoma.
TECHNOLOGIES IN CLINICAL DEVELOPMENT
Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO)
Antibody Toxin Conjugates (ATCs)
OUR SCIENCE
Find out more about our breakthrough PVSRIPO platform
PIPELINE
For more on how our technologies are advancing
NEWS
Access the latest updates and research